Repurposing celecoxib for colorectal cancer targeting via pH-triggered ultra-elastic nanovesicles : Pronounced efficacy through up-regulation of Wnt/β-catenin pathway in DMH-induced tumorigenesis
© 2023 The Authors. Published by Elsevier B.V..
Celecoxib (CLX), a selective inhibitor for cyclooxygenase 2 (COX-2), has manifested potential activity against diverse types of cancer. However, low bioavailability and cardiovascular side effects remain the major challenges that limit its exploitation. In this work, we developed ultra-elastic nanovesicles (UENVs) with pH-triggered surface charge reversal traits that could efficiently deliver CLX to colorectal segments for snowballed tumor targeting. CLX-UENVs were fabricated via a thin-film hydration approach. The impact of formulation factors (Span 80, Tween 80, and sonication time) on the nanovesicular features was evaluated using Box-Behnken design, and the optimal formulation was computed. The optimum formulation was positively coated with polyethyleneimine (CLX-PEI-UENVs) and then coated with Eudragit S100 (CLX-ES-PEI-UENVs). The activity of the optimized nano-cargo was explored in 1,2-dimethylhydrazine-induced colorectal cancer in Wistar rats. Levels of COX-2, Wnt-2 and β-catenin were assessed in rats' colon. The diameter of the optimized CLX-ES-PEI-UENVs formulation was 253.62 nm, with a zeta potential of -23.24 mV, 85.64% entrapment, and 87.20% cumulative release (24 h). ES coating hindered the rapid release of CLX under acidic milieu (stomach and early small intestine) and showed extended release in the colon section. In colonic environments, the ES coating layer was removed due to high pH, and the charge on the nanovesicular corona was shifted from negative to positive. Besides, a pharmacokinetics study revealed that CLX-ES-PEI-UENVs had superior oral bioavailability by 2.13-fold compared with CLX suspension. Collectively, these findings implied that CLX-ES-PEI-UENVs could be a promising colorectal-targeted nanoplatform for effective tumor management through up-regulation of the Wnt/β-catenin pathway.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
International journal of pharmaceutics: X - 7(2024) vom: 20. Jan., Seite 100225 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
El Menshawe, Shahira F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Box-Behnken design |
|---|
| Anmerkungen: |
Date Revised 18.01.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.ijpx.2023.100225 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367209675 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367209675 | ||
| 003 | DE-627 | ||
| 005 | 20240118232146.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240117s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpx.2023.100225 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1263.xml |
| 035 | |a (DE-627)NLM367209675 | ||
| 035 | |a (NLM)38230407 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a El Menshawe, Shahira F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repurposing celecoxib for colorectal cancer targeting via pH-triggered ultra-elastic nanovesicles |b Pronounced efficacy through up-regulation of Wnt/β-catenin pathway in DMH-induced tumorigenesis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. Published by Elsevier B.V. | ||
| 520 | |a Celecoxib (CLX), a selective inhibitor for cyclooxygenase 2 (COX-2), has manifested potential activity against diverse types of cancer. However, low bioavailability and cardiovascular side effects remain the major challenges that limit its exploitation. In this work, we developed ultra-elastic nanovesicles (UENVs) with pH-triggered surface charge reversal traits that could efficiently deliver CLX to colorectal segments for snowballed tumor targeting. CLX-UENVs were fabricated via a thin-film hydration approach. The impact of formulation factors (Span 80, Tween 80, and sonication time) on the nanovesicular features was evaluated using Box-Behnken design, and the optimal formulation was computed. The optimum formulation was positively coated with polyethyleneimine (CLX-PEI-UENVs) and then coated with Eudragit S100 (CLX-ES-PEI-UENVs). The activity of the optimized nano-cargo was explored in 1,2-dimethylhydrazine-induced colorectal cancer in Wistar rats. Levels of COX-2, Wnt-2 and β-catenin were assessed in rats' colon. The diameter of the optimized CLX-ES-PEI-UENVs formulation was 253.62 nm, with a zeta potential of -23.24 mV, 85.64% entrapment, and 87.20% cumulative release (24 h). ES coating hindered the rapid release of CLX under acidic milieu (stomach and early small intestine) and showed extended release in the colon section. In colonic environments, the ES coating layer was removed due to high pH, and the charge on the nanovesicular corona was shifted from negative to positive. Besides, a pharmacokinetics study revealed that CLX-ES-PEI-UENVs had superior oral bioavailability by 2.13-fold compared with CLX suspension. Collectively, these findings implied that CLX-ES-PEI-UENVs could be a promising colorectal-targeted nanoplatform for effective tumor management through up-regulation of the Wnt/β-catenin pathway | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Box-Behnken design | |
| 650 | 4 | |a Celecoxib | |
| 650 | 4 | |a Colorectal cancer targeting | |
| 650 | 4 | |a Pharmacokinetics | |
| 650 | 4 | |a Wnt/β-catenin pathway | |
| 650 | 4 | |a pH-triggered charge-reversal nanovesicles | |
| 700 | 1 | |a Shalaby, Khaled |e verfasserin |4 aut | |
| 700 | 1 | |a Elkomy, Mohammed H |e verfasserin |4 aut | |
| 700 | 1 | |a Aboud, Heba M |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Yasmin M |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelmeged, Abdelmeged A |e verfasserin |4 aut | |
| 700 | 1 | |a Elkarmalawy, Marwa |e verfasserin |4 aut | |
| 700 | 1 | |a Abou Alazayem, Mahmoud A |e verfasserin |4 aut | |
| 700 | 1 | |a El Sisi, Amani M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics: X |d 2019 |g 7(2024) vom: 20. Jan., Seite 100225 |w (DE-627)NLM301258015 |x 2590-1567 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2024 |g day:20 |g month:01 |g pages:100225 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijpx.2023.100225 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2024 |b 20 |c 01 |h 100225 | ||